Is this really the end of beta-blockers in patients with cirrhosis and refractory ascites?
Thevenot
Thierry
T
Cervoni
Jean-Paul
JP
Monnet
Elisabeth
E
Sheppard
Frances
F
Martino
Vincent Di
VD
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D001201:Ascites / Q000188:drug therapy* / Q000401:mortality; D000075202:Contraindications; D006801:Humans; D006975:Hypertension, Portal / Q000401:mortality / Q000503:physiopathology; D008103:Liver Cirrhosis / Q000188:drug therapy* / Q000401:mortality; D011433:Propranolol / Q000627:therapeutic use; D015996:Survival Rate; D016896:Treatment Outcome
D000319:Adrenergic beta-Antagonists; D011433:Propranolol